MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma multiforme [Multiforme MR perfusion og FLT- og FET-PET i løbet af Bevacizumab monoterapi for recidiverende Glioblastoma multiforme].

Trial Profile

MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma multiforme [Multiforme MR perfusion og FLT- og FET-PET i løbet af Bevacizumab monoterapi for recidiverende Glioblastoma multiforme].

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 32 to 16.
    • 09 Nov 2012 Planned end date changed from 5 Jan 2013 to 5 Jan 2016 as reported by European Clinical Trials Database.
    • 19 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top